BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19

• Press Releases

  Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas

  December 12, 2025

   · 

  4 min read
• Press Releases

  Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

  December 12, 2025

   · 

  7 min read
• Press Releases

  FDA Approves USAntibiotics’ Augmentin XR in Historic First for Expedited Review Program

  December 12, 2025

   · 

  2 min read
• Press Releases

  The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring of localized HER2+ breast cancer

  December 12, 2025

   · 

  6 min read
• Press Releases

  Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

  December 12, 2025

   · 

  5 min read
• Press Releases

  Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

  December 12, 2025

   · 

  5 min read
• Press Releases

  Subsense Expands Financing to $27 Million to Accelerate R&D for Non-Surgical Brain-Computer Interfaces

  December 12, 2025

   · 

  2 min read
• Press Releases

  Science Corporation Names Darius Shahida as Chief Strategy Officer

  December 12, 2025

   · 

  3 min read
• Press Releases

  Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).

  December 12, 2025

   · 

  3 min read
• Press Releases

  Prilenia and Ferrer Announce FDA Clearance to Start the “PREVAiLS” Pivotal Phase 3 Study with Pridopidine in ALS

  December 12, 2025

   · 

  9 min read